BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancersZannel Blanchard(University of Mississippi Medical Center), Wael M. ElShamy(San Diego Biomedical Research Institute)Breast Cancer ResearchJanuary 12, 201510.1186/s13058-014-0512-9Cited by 49SaveCiteExport RISWatch citationsRelated PapersNetwork modeling links breast cancer susceptibility and centrosome dysfunction|Nature Genetics|2007|634Geminin overexpression prevents the completion of topoisomerase IIα chromosome decatenation, leading to aneuploidy in human mammary epithelial cells|Breast Cancer Research|2011|32Geminin Overexpression Promotes Imatinib Sensitive Breast Cancer: A Novel Treatment Approach for Aggressive Breast Cancers, Including a Subset of Triple Negative|PLoS ONE|2014|26Geminin overexpression-dependent recruitment and crosstalk with mesenchymal stem cells enhance aggressiveness in triple negative breast cancers|Oncotarget|2016|22